2. Search Result
Search Result
Results for "

MTAP -/-

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133023
    Indium(III) isopropoxide

    		Others Others
    Indium(III) Isopropoxide is an organo-metallic compound. Indium(III) Isopropoxide uesd as a hydrogen transfer catalyst for conversion of benzylic alcohols into aldehydes or ketones via Oppenauer oxidation. Indium(III) Isopropoxide also can be used as metal precursor .
    Indium(III) isopropoxide
  • HY-148419
    TNG908

    		Histone Methyltransferase Cancer
    TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research .
    TNG908
  • HY-112130
    AGI-24512
    1 Publications Verification

    		 Methionine Adenosyltransferase (MAT) Cancer
    AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer .
    AGI-24512
  • HY-RS08749
    MTAP Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MTAP Human Pre-designed siRNA Set A contains three designed siRNAs for MTAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MTAP Human Pre-designed siRNA Set A
    MTAP Human Pre-designed siRNA Set A
  • HY-155149
    MAT2A-IN-12

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP -/- cell line) .
    MAT2A-IN-12
  • HY-101496
    MT-DADMe-ImmA
    2 Publications Verification

    MTDIA; Methylthio-DADMe-Immucillin A

    		 Others Cancer
    MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a Ki of 90 pM.
    MT-DADMe-ImmA
  • HY-162010
    MAT2A-IN-13

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research .
    MAT2A-IN-13
  • HY-156680
    TNG-462

    		Histone Methyltransferase Cancer
    TNG-462 (Compound 1143) is an orally active PRMT5 inhibitor for investigation of MTAP-deficient and/or MTA-accumulating cancers .
    TNG-462
  • HY-112129
    AGI-25696

    		Methionine Adenosyltransferase (MAT) Cancer
    AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.
    AGI-25696
  • HY-162353
    AZ'9567

    		Methionine Adenosyltransferase (MAT) Cancer
    AZ9567 is a potent MAT2A inhibitor. AZ9567 exhibits antiproliferative activity against MTAP KO HCT116 cells with a pIC50 of 8.9 .
    AZ'9567
  • HY-139611C
    MRTX-1719 hydrochloride

    		Histone Methyltransferase Cancer
    MRTX-1719 hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells .
    MRTX-1719 hydrochloride
  • HY-16933
    L-Alanosine
    1 Publications Verification

    NSC-153353; SDX-102

    		 Antibiotic Infection Cancer
    L-Alanosine (NSC-153353), an antibiotic from Streptomyces alanosinicus, has antineoplastic activity. L-Alanosine (NSC-153353) inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate. L-Alanosine (NSC-153353) blocks the common de novo purine biosynthesis pathway and, thereby, inhibits tumor cells with MTAP deficiency .
    L-Alanosine
  • HY-144181
    MAT2A-IN-5

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
    MAT2A-IN-5
  • HY-144184
    MAT2A-IN-6

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
    MAT2A-IN-6
  • HY-144185
    MAT2A-IN-7

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
    MAT2A-IN-7
  • HY-142930
    MAT2A-IN-3

    		Somatostatin Receptor Cancer
    MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
    MAT2A-IN-3
  • HY-142929
    MAT2A-IN-2

    		Somatostatin Receptor Cancer
    MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
    MAT2A-IN-2
  • HY-142928
    MAT2A-IN-1

    		Somatostatin Receptor Cancer
    MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
    MAT2A-IN-1
  • HY-138684
    MRTX9768

    		Histone Methyltransferase Cancer
    MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768
  • HY-138684A
    MRTX9768 hydrochloride

    		Histone Methyltransferase Cancer
    MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: